ORLANDO, FL, USA (UroToday.com) - Despite the number of novel therapies for patients with metastatic prostate cancer, there is little data on the impact of time to metastasis on survival. Shusuke Akamatsu and colleagues evaluated the institutional data of the Vancouver Prostate Centre for survival according to time to metastasis.
One hundred and fifty-seven CRPC patients were identified from 2008-2013, of which 92 had mets and complete data. Thirty-five had mets within 3 months of initial diagnosis (“de novo mets”), 26 had mets more than 6 months prior to CRPC (CSPC-M), and 31 had mets that were identified within 6 months of becoming castrate resistant or after becoming castrate resistant (CRPC-M). Eighty-five percent of CSPC-M and 84% of CRPC-M had local therapy by surgery or radiation. Mean time to PSA recurrence was 3.5 years in the CSPC-M group and 2.2 years in the CRPC-M group, while median time to mets was 4.4 and 11.4 years. Median time to CRPC was 1.4 years in the de novo group, 6.2 years in the CSPC-M group, and 8.6 years in the CRPC-M group, while OS was 3.7, 12.3, and 15.8 years, respectively.
The authors concluded that OS and time to CRPC was significantly shorter in the de novo group. There was no significant difference in OS between CSPC-M and CRPC-M despite the difference in time to mets.
Presented by Shusuke Akamatsu at the 2015 Genitourinary Cancers Symposium - "Integrating Biology Into Patient-Centric Care" - February 26 - 28, 2015 - Rosen Shingle Creek - Orlando, Florida USA
Vancouver Cancer Centre, Vancouver, BC Canada
Reported by Nikhil Waingankar, MD, medical writer for UroToday.com